Research programme: targeted apoptosis stimulants - AntisomaAlternative Names: AS 1406; HMFG1-RNase; huHMFG1-RNase; TheraNase
Latest Information Update: 17 Sep 2007
At a glance
- Originator Antisoma; National Cancer Institute (USA)
- Developer Antisoma
- Class Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer